Description and Characterisation of Asthmatics Eligible for Biologic Therapy Referral Among Primary and Secondary Care Settings in Europe (RECOGNISE Study)
Phase of Trial: Phase IV
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Benralizumab (Primary) ; Mepolizumab (Primary) ; Omalizumab (Primary) ; Reslizumab (Primary)
- Indications Asthma
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms RECOGNISE
- Sponsors AstraZeneca
- 18 Jun 2019 Planned End Date changed from 1 Oct 2019 to 1 Nov 2019.
- 18 Jun 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.
- 17 Apr 2019 Planned number of patients changed from 2000 to 1650.